Personal Genome Diagnostics

Leading the way in patient-specific cancer genome analysis with groundbreaking technologies for non-invasive liquid biopsy approaches.

Founded 2010 0-1 employees Series C Total: $244.70M Analytics, Biotechnology +2

Personal Genome Diagnostics (PGDx) is a pioneering company in patient-specific cancer genome analysis, utilizing advanced tools and technologies in analytics and biotechnology. Founded in 2010 and headquartered in Baltimore, Maryland, United States, the company has been at the forefront of sequencing and analyzing entire human cancer exomes, identifying crucial alterations contributing to cancer development. PGDx specializes in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes, while also spearheading innovative technologies for non-invasive liquid biopsy approaches in cancer. The company recently secured a significant $103.00M Series C investment on 10 February 2021, with contributions from a diverse group of investors including New Enterprise Associates, Windham Venture Partners, Sands Capital Ventures, Catalio Capital Management, Cowen Digital, Innovatus Capital Partners, Northpond Ventures, PFM Health Sciences, Vensana Capital, and Kern Capital. This investment aligns with PGDx's mission to provide tailored cancer genome analyses and share proprietary methods and expertise with research teams globally, ultimately assisting oncologists and translational scientists in understanding various aspects of the disease. In summary, Personal Genome Diagnostics epitomizes innovation in cancer genome analysis, with a focus on non-invasive liquid biopsy approaches and a commitment to advancing the understanding of cancer through cutting-edge technology and expertise.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$103.00M	10	New Enterprise Associates, Windham Venture Partners +8	10 Feb 2021
Venture Round	$42.00M	1	Innovatus Capital Partners	04 Oct 2018
Series B	$75.00M	7	New Enterprise Associates, Maryland Venture Fund +5	04 Jan 2018
Series A	$21.40M	3	New Enterprise Associates, Windham Venture Partners +1	28 Oct 2015
Angel Round	$2.80M	-		02 Apr 2014
Seed Round	$500.00K	-		31 Aug 2011

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

$103.00M

New Enterprise Associates, Windham Venture Partners +8

10 Feb 2021

Venture Round

$42.00M

Innovatus Capital Partners

04 Oct 2018

Series B

$75.00M

New Enterprise Associates, Maryland Venture Fund +5

04 Jan 2018

Series A

$21.40M

New Enterprise Associates, Windham Venture Partners +1

28 Oct 2015

Angel Round

$2.80M

02 Apr 2014

Seed Round

$500.00K

31 Aug 2011

FAQ About Personal Genome Diagnostics

Leading the way in patient-specific cancer genome analysis with groundbreaking technologies for non-invasive liquid biopsy approaches.

Personal Genome Diagnostics was founded in 2010.

Personal Genome Diagnostics operates in Analytics, Biotechnology, Health Care and Clean Energy. Its work centres on Cancer Genetics, DNA-based Cancer Diagnostics, Whole Exome Sequencing and Targeted Cancer Gene Sequencing.

Personal Genome Diagnostics has approximately 0-1 employees.

Personal Genome Diagnostics has completed 6 funding rounds, raising a total of $244.70M. The latest funding stage is Series C.

Top alternatives and competitors to Personal Genome Diagnostics include GeneCast Biotechnology Co., Ltd., Geninus Inc. , Helix, Annoroad Genomics, Diatech Pharmacogenetics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Personal Genome Diagnostics and GeneCast Biotechnology Co., Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Personal Genome Diagnostics

General Information

Discover More

About Personal Genome Diagnostics

Funding Rounds & Investors (6)

Personal Genome Diagnostics Alternatives & Competitors

FAQ About Personal Genome Diagnostics